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Background: Selective Alzheimer Disease Indicator-1 (or Seladin-1) is a multifunctional protein first discovered by
downregulation of its expression in Alzheimer’s disease. Interestingly, the expression of this protein is upregulated
in several cancers, including primary bladder cancer. However, its role in cancer formation has yet to be discovered.
Goniothalamin is a natural product that has been demonstrated to induce apoptosis in various cancer cell lines. In
this study, we have elucidated the role of Seladin-1 in goniothalamin-induced cytotoxicity towards human urinary
bladder cancer cell line RT4.
Methods: The cytotoxicity of goniothalamin in human urinary bladder cancer cell line RT4 was assessed using MTT
assay and the mode of cell death was determined by Annexin V-FITC/PI labeling assay. Finally, the expression of
Seladin-1 protein in goniothalamin-treated RT4 cells was determined by Western blot.
Results: MTT assay showed that the cytotoxicity of goniothalamin on RT4 cells was concentration and time
dependent with IC50 values of 61 μM (24 hr), 38 μM (48 hr) and 31 μM for 72 hr, respectively. Cell death induced was
confirmed through apoptosis; as assessed using the Annexin V-FITC/PI labeling assay. Furthermore, the involvement of
Seladin-1 in goniothalamin-induced apoptosis was evidenced through the cleavage of 60 kDa protein to 40 kDa and
20 kDa. This was followed by a gradual increase of 20 kDa fragment suggesting the involvement of Seladin-1 in
goniothalamin-induced apoptosis on RT4 cells.
Conclusion: This study demonstrates that goniothalamin induce cytotoxicity and apoptosis on RT4 cells. The
involvement of Seladin-1 in goniothalamin-induced apoptosis further suggested that Seladin-1 may play a role in the
formation of primary bladder cancer.
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The urinary bladder functions as a temporary storage for
urine before being excreted out from the body. It is
composed of layers of transitional epithelium; including
smooth muscle, which allows the organ to expand and
contract [1]. It is an organ highly prone to cancer of
genitourinary system, with 90% of the cancer being tran-
sitional cell carcinoma, whilst the rest are squamous and* Correspondence: nfadilah@medic.ukm.my
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unless otherwise stated.adenocarcinoma [2]. The etiology of urinary bladder
cancer include tobacco smoking, occupational exposure
to chemical carcinogens, such as aromatic amine and
Schistosomal infections [3,4]. The progression of cancer
is a multistep process that includes genetic alteration; as
the deregulation (or mutation) of certain genes may pre-
dispose to certain cancers. According to Doherty and
coworkers, different gene expressions that were found at
two anatomical areas (ureteric orifice and dome) of
normal bladders are commonly prone to have primary
bladder cancer. The expressions of these genes may give
some insight into bladder carcinogenesis; especially
Seladin-1, which was found upregulated at the ureteric. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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involvement especially in cancers [5-7].
Selective Alzheimer’s disease Indicator 1 (or Seladin-1)
was first discovered in Alzheimer’s disease. This gene
has an anti-apoptotic function in brain tissue, whereby
its downregulation has been associated with neuro-
degeneration [8]. Seladin-1 was found to be identical to
the gene DHCR24, which functions as a key enzyme in
cholesterol biosynthesis and lipid raft formation [9,10].
It was also described as a multifunctional protein. In
cancer, Seladin-1 was found highly expressed in adrenal
cancer, pituitary tumors, urinary bladder cancer, mela-
noma, and prostate cancer [7,11-14]. The high expres-
sion of Seladin-1 found in those cancers may have been
due to high cholesterol content; however, the signifi-
cance of Seladin-1 in cancer was not fully elucidated.
From previously reported literature, we strongly believe
in the involvement of Seladin-1 in carcinogenesis. It has
also been shown that Seladin-1 was cleaved by caspase-
6 and caspase-3, which proved Seladin-1 act as a death
substrate for caspases and may function as pro-apop-
totic element upon cleavage [8]. According to previous
studies, upon oncogenic induction and oxidative stress,
Seladin-1 was found to bind p53 and displace mdm-2
resulted in the accumulation of active p53. This inter-
action suggests a role of Seladin-1 in the regulation of
cell fate [15]. In addition, Seladin-1 was demonstrated
as lipopolysaccharide (LPS) responsive gene product
that regulates anti-inflammatory response [16].
Goniothalamin is a natural product isolated from
Goniothalamus species, which is abundantly found in
Malaysia. This styryl lactone derivative possesses potent
cytotoxic activity and induces apoptosis in various can-
cer cell lines; such as liver, breast, kidney, ovarian and
leukemic cell lines [17-23]. Recent studies have de-
monstrated the anti-inflammatory and antiproliferative
effect of goniothamin in vivo to further confirm the
potential of goniothalamin and its related molecules as
a therapeutic agent [24]. The mechanism of goniothala-
min-induced apoptosis was found involves oxidative
stress and mitochondria mediated pathway [17,25].
Previous studies have shown that goniothalamin induces
DNA damage, generation of reactive oxygen species (ROS),
loss of mitochondria membrane potential, release of
cytochrome c and activation of caspases [17,18,21,22,25].
Goniothalamin-induced apoptosis mainly via intrinsic
pathway; however, the full mechanism is yet to be eluci-
dated. Thus, in this study, the cytotoxicity of goniotha-
lamin was assessed using MTT assay in urinary bladder
cancer cell line RT4 and etoposide, a known cytotoxic
agent was used as a positive control. The determination
of apoptosis event and the involvement of Seladin-1 in
goniothalamin-induced apoptosis were also elucidated, to
further understand the underlying mechanism.Methods
Goniothalamin
The compound goniothalamin was provided by Professor
Dato Dr. Laily Bin Din from Universiti Kebangsaan
Malaysia (Bangi). It was isolated from G. andersonii as de-
scribed previously [17,26], a stock solution of 50 mM
goniothalamin was prepared by dissolving in DMSO (Ajax
Finechem) with the final concentration less than 1%.
Cell line & reagents
Urinary bladder cancer cell lines RT4 was obtained from
ATCC and cultured in McCoy’s 5A medium (Gibco) sup-
plemented with 10% fetal bovine serum and 1% penicillin/
streptomycin. Cells were subcultured every two days with
0.25% trypsin/ 1.5 mM EDTA and maintained at 37°C
under 5% CO2 environment. The RT4 cells used in this
study were within 10 passages.
MTT assay
The cytotoxicity of goniothalamin on RT4 cells was
assessed by MTT assay as described previously [25,27].
RT4 cells were seeded in a 96 well microplate at a con-
centration of 5 × 104 cells per well and incubated 24 hrs.
Next, a fresh medium containing tested compound was
added. The concentrations of goniothalamin used were
6.25, 12.5, 25, 50 and 100 μM and etoposide were 18.75,
37.5, 75, 150 and 300 μM. Cells were treated for 24, 48
and 72 hrs. After treatment, 20 ul MTT (5 mg/ml) was
added and further incubated for 4hrs. Supernatant was
then discarded and replaced with 200ul DMSO. The
microplate was incubated for 15m and shaken to dis-
solve the crystal formazan. The viability of the cells was
determined by measuring the absorbance of each well
on an ELISA plate reader (Biorad) at 570 nm. The per-
centage viability of the cells was determined by com-
paring the mean absorbance of treated cells to untreated
cells. A graph was plotted with percentage viability
versus concentration of the tested compound and IC50
value was obtained.
Annexin V-FITC/PI labeling assay
Determinations of the mode of cell death or the apoptosis
event induced by the goniothalamin on RT4 cells were
assessed by Annexin V-FITC/PI labeling assay, as de-
scribed previously [25]. RT4 cells were seeded at 1 × 106
cells per well in a six well plate and incubated for 24 hrs,
followed by treatment of goniothalamin at concentrations
of 50, 61 (IC50) and 100 μM, and treatment of etoposide
at 46 μM (IC50) act as positive control, and incubated for
24hrs. After treatment, cells were harvested. Medium and
floaters from each well were collected and cells were rinse
with PBS and incubated with trypsin/EDTA until 80% of
the cells were detached. All cell suspensions were col-
lected and centrifuged at 220 × g for 5 mins. Next, the
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with chilled PBS and centrifuged at 220 × g for 5 mins at
4°C. Pellets were washed twice and the supernatant was
discarded. Next, 150 μl of chill Annexin V binding buffer
was added, followed by 5 μl of Annexin V-FITC (BD Phar-
mingen) and incubated for 15 mins. During the final 2
mins, 5 μl of propidium iodide (50 μg/ml) was added and
further incubated. After staining, 350 μl of Annexin V
binding buffer was added and all of the samples were
transferred to Falcon flow tubes for analysis using FACS-
Canto Flow Cytometer (BD Bioscience, USA).
Western blotting
RT4 cells were seeded at a concentration of 2.5 × 105
cells/ml on a tissue culture dish and incubated for 24 hrs.
Next, the cells were treated with goniothalamin at the
concentration of 61 μM (IC50) for 2, 4, 8, 16, and 24 hrs.
Following treatment, cell lysates were collected and pro-
tein samples were prepared and denatured at 95°C for 5
mins. Next, 20 μg/ml lysate was resolved on 12% SDS-
polyacrylamide gel electrophoresis and blotted onto a
polyvinylidene fluoride membrane. Western blotting was
carried out as described previously [18]. Rabbit mono-
clonal anti-Seladin-1 antibody (Sigma, USA) was used at a
dilution of 1:5000 in 5% skimmed milk and incubated at
4°C overnight. Meanwhile, rabbit monoclonal beta actin
antibody (Cell Signaling, USA) was used at a dilution
of 1:10000. After incubation of the primary antibody,
secondary antibody (goat anti-rabbit HRP conjugated
antibody, Cell Signaling, USA) was added and incuba-
ted for 1 hr. prior to detection by chemiluminenscene
(Amersham, UK).
Statistical analysis
All experiments were repeated three times and data



























Figure 1 Percentage of viability of RT4 cells treated by goniothalamin
represents mean ± SEM of 3 different experiments (*p < 0.05 compare to cperformed using Statistical Package for Social Science
(SPSS) version 21 and One Way ANOVA post-hoc tech-




The cytotoxic effect of goniothalamin on RT4 cells was
assessed by MTT assay. Following treatment of 24, 48 and
72 hr, the percentage viability of the cells was obtained
and graph was plotted versus concentration of goniothala-
min (see Figure 1). The graph shows that the IC50 value
was 61 μM, 38 μM and 31 μM following 24 hrs, 48 hrs
and 72 hrs treatment, respectively. The viability drop from
100% from control and further reduced across concentra-
tions of goniothalamin and time points; with the highest
concentration (100 μM) of goniothalamin showed less
than 20% of cells were viable following 24 hrs, 48 hrs, and
72 hrs of treatment. Statistical analysis showed that there
was a significant reduction in the percentage of cell via-
bility following treatment with goniothalamin at each con-
centration (i.e., 6.25, 12.5, 25, 50, and 100 μM) compared
to control or untreated cells (p < 0.05). Etoposide was used
as a positive control for this experiment and the results of
the cytotoxic effect are shown in Figure 2. The IC50 value
of etoposide on RT4 cells was 46 μM, 15 μM and 14 μM
following 24 hrs, 48 hrs and 72 hrs treatment, respectively.
There was a significant reduction in percent viability
compared to the control at each concentration of etopo-
side (p < 0.05).
Annexin V-FITC/PI labeling
Goniothalamin was known to induce cell death with
mainly through apoptosis at various cell lines [17-23]. In
this study mode of cell death or determination of apop-






































Figure 2 Percentage of viability of RT4 cells treated by etoposide (18.75, 37.5, 75, 150, and 300 μM) for 24, 48, and 72 hrs. Each point
represents mean ± SEM of 3 different experiments (*p < 0.05 compared to the control).
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Labeling assay as described previously [25], at the con-
centration of 50, 61 (IC50) &100 μM of goniothalamin
following 24 hr treatment. Three concentration of go-
niothalamin was chosen in order to understand the
concentration dependent cell death event induced by
goniothalamin. By using Annexin V-FITC/PI staining,
apoptosis and necrosis event was quantified by flow cy-
tometry as shown in Figure 3. The cytogram quadrant of
annexin V staining positive represent apoptotic event and
PI staining positive represent necrotic event. Quadrant 1
(Q1) is the region of necrotic event where annexin V
staining negative and PI staining positive. Q2 is late apop-
tosis event where both annexin V and PI staining positive,
Q4 is early apoptosis event with cells stained with annexin
V alone and Q3 represent event of negative staining for
both annexin V and PI. Based on the result, there was an
increased in the apoptosis event with the increase of
goniothalamin concentration. At 50 μM, 53.6% of the cells
are apoptotic, whereas 63.8% are apoptotic at 61μM treat-
ment and 70.5% at 100 μM, respectively. However, etopo-
side showed only 25.1% of apoptosis event. Only small
percentages of cells were necrotic. Vehicle control or un-
treated cell was also assessed to ensure the viability of cell
for each experiment, majority all the event fall into Q 3
which was 81.9% of cell stained negative for both stain.
Statistical analysis showed significant apoptosis event
compare to untreated cells with p < 0.05, with no signifi-
cant difference for necrotic events.
Western blotting
The involvement of Seladin-1 protein on induction by
goniothalamin was assessed using Western blotting (as
shown in Figure 4). RT4 cells were treated by IC50 of
goniothalamin at 2, 4, 8, 16, and 24 hrs to assess theexpression of Seladin-1. The results showed that there
was a cleavage of Seladin-1 from 60 kDa to 40 kDa, and
20 kDa as increase in treatment time, and the 40 kDa
fragment was gradually decreased but not visualized at a
later time point. On the contrary, the 20 kDa fragment
was gradually increased from 8, 16, and 24 hours.
Discussion
Goniothalamin induced cytotoxicity and antiproliferative
on RT4 cells
Goniothalamin is a styryl lactone derivative that has been
proved to have cytotoxic activity and induce apoptosis in a
variety of cancer cell lines [28]. However, the cytotoxicity
of goniothalamin on urinary bladder cancer has not been
assessed before. Therefore, in this study, urinary bladder
cancer cell line RT4 was employed to determine the
cytotoxicity of goniothalamin on urinary bladder cancer.
RT4 cells were treated by goniothalamin 6.25, 25, 50, and
100 μM for 24 hrs, 48 hrs, and 72 hrs. Results showed that
IC50 for 24 hrs was 61 μM; which was higher than pre-
vious studies [23,28]. Therefore, the treatment time was
extended to 48 hrs and 72 hrs; where IC50 for 48 hrs treat-
ment was 38 μM and 31 μM for 72 hrs respectively. Ac-
cording to previous studies, goniothalamin was able to
induce cytotoxic and apoptosis at micro molar concentra-
tions; Chan and coworkers have demonstrated that the
IC50 value for 72 hr treatment was 22 μM on vascular
smooth muscle cells [28]. This result and our findings in-
dicate that goniothalamin is able to induce concentration
and time dependent cytotoxic and antiproliferative effects;
the effect of which may depend on sensitivity, stage, and
type of cancer. An RT4 cell has the characteristic similar
to superficial bladder tumor with bearing wild type p53
[29]. According to Al-Sukhun and coworkers, aberration
of tumor suppressor gene such as p53 was associated with
Figure 3 Flow cytometry profile of RT4 cells treated by goniohtalamin (GTN) at 50, 61.3 (IC50), and 100 μM, etoposide IC50 for 24 hrs.,
a) Untreated cells (VC) b) GTN 50 μM; c) IC50 GTN d) 100 μM GTN and e) etoposide IC50.
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Figure 4 Expression of Seladin-1 on RT4 cells after treatment
by IC50 (61 μM) of goniothalamin at 2, 4, 8, 16, and 24 hrs.
Vehicle control (or untreated cells) acted as a negative control and
β-actin as a loading control during the experiment.
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ness of the tumor to chemotherapeutic agents [30]. This
may explained the higher IC50 value in this study.
Goniothalamin induced apoptosis on RT4 cells
Apoptosis was assessed using Annexin V-FITC/PI stai-
ning. The assay utilized Annexin V, which is a protein that
binds to phosphatidylserine (PS) when cells undergo
apoptosis. The externalization of PS was an early event of
apoptosis; thus, by using annexin V, conjugated with a
fluorochrome (FITC), the event of apoptosis could be
quantified by flow cytometer. Based on the results ob-
tained, goniothalamin was able to induce apoptosis on
RT4 cells after 24 hrs treatment. Event of apoptosis were
concentration dependent, where treatment with 100 μM
of goniothalamin gave the highest apoptosis event (70.5%).
When comparing IC50 of etoposide, 46 μM to IC50 of
goniothalamin, events of apoptosis were higher in go-
niothalamin. This may have been due to different end
points of each assay used to detect cell viability and apop-
tosis, as MTT assay only measured the activation of the
mitochondria enzyme [27], while annexin v-FITC labeling
was able to detect the flipping of PS on the apoptosis cells
[31]. However, in some incidents, the flip-flop of PS may
also have occurred as a late event; and in this research,
etoposide only acted as a positive control for experiment
validation [32]. In addition, necrotic events induced by
goniothalamin were less than 10%, which similar to pre-
vious studies on various cancer cell lines including cervical
cancer, leukemia, vascular smooth muscle cells, and breast
cancer cells [23,25].
Involvement of Seladin-1 in goniothalamin induced
apoptosis
Previous studies have shown that styryl lactone compound
from Goniothalamus sp was able to induce apoptosis via
activation of caspases enzyme cascade, release of cyto-
chrome c, loss of mitochondrial membrane potential, and
increase expression of pro-apoptotic BH3 protein [33].
Therefore, goniothalamin was used in this study asapoptotic inducer to elucidate the role of Seladin-1 in
goniothalamin induced apoptosis on human bladder can-
cer cell line RT4. Upon treatment with goniothalamin, we
observed that Seladin-1 was cleaved from 60 kDa to 40
kDa, and 20 kDa. As increase in treatment time, the 40
kDa fragment was undetectable. However, the 20 kDa
showed a gradual increased. This result was comparable
to previous studies by Greeve and coworker, which
showed that upon induction of apoptosis by growth factor
deprivation, Seladin-1 was cleaved by caspase-3 and cas-
pase 6 to 4 multiple fragments of 20, 30, 40, and 50 kDa
on human umbilical vein endothelial cells [8]. However, in
this study, instead of a 40 kDa fragment, goniothalamin
treatment was able to induce a cleavage of Seladin-1 to 20
kDa on RT4 cells. This cleavage was believed to be mainly
due to the activation of caspase-3. In accordance with pre-
vious studies, caspase-3 was the primary executioner of
caspases activated during goniothalamin-induced apop-
tosis [17,18,25]. Therefore, in this study, we are in agree-
ment with Greeve and coworker that Seladin-1 was a
caspase-3 substrate and following the induction of apop-
tosis by goniothalamin, Seladin-1 was believed to be
cleaved and the expression increased; which may resulted
in changes of function from anti-apoptotic to pro-apop-
totic (as shown in this study). In addition, this evidence
also suggested that Seladin-1, which function as anti-
apoptotic protein, may play a role in the formation of
primary bladder cancer. Hence, Seladin-1 can act as a
therapeutic target for urinary bladder cancer, or as a
screening marker for primary tumors.
Conclusion
Goniothalamin induced cytotoxicity through apoptosis in
human urinary bladder cancer cell line RT4, in concentra-
tion and time dependent manner. The involvement of
Seladin-1 was observed with increased expression of
cleaved fragment (20 kDa) further suggested its role in
goniothalamin-induced apoptosis and formation of pri-
mary cancer. However, further investigation is needed to
elucidate the role of Seladin-1 in urinary bladder cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NFR Contribution: Participate in the design of study, analysis and
interpretation of data; provide important scientific input for result analysis
and manuscript preparation. KYH Contribution: Carried out experiment,
analysis and interpretation of data, drafted manuscript. ARF Contribution:
Carried out experiment, analysis and interpretation of data, drafted
manuscript. LBD Contribution: Isolate and provide the studied compound,
goniothalamin. VJM-M Contribution: Provide important scientific input for
the design of study. KMC Contribution: Participate in the design of study,
analysis and interpretation of data; provide important scientific input for
result analysis and discussion. SHI-H Contribution: Participate in the design of
study, analysis and interpretation of data; provide important scientific input
for result analysis and discussion. All authors read and approved the final
manuscript.
Yen et al. BMC Complementary and Alternative Medicine 2014, 14:295 Page 7 of 7
http://www.biomedcentral.com/1472-6882/14/295Acknowledgement
This research work was financially supported by the research grant UKM-NN-06-
FRGS-0143-2010, UKM-DLP-2011-010 and DIP-2012-024. We would like to
acknowledge the Center for Research and Instrumentation Management (CRIM),
UKM for providing the flow cytometry facility.
Author details
1Biomedical Science Programme, Faculty of Health Sciences, Universiti
Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur,
Malaysia. 2Faculty of Science and Technology, Universiti Kebangsaan
Malaysia, Bangi 43600, Selangor, Malaysia. 3School of Pharmacy and
Pharmaceutical Sciences, University of Ulster, Coleraine BT52 1SA, United
Kingdom. 4Environmental Health and Industrial Safety Science Programme,
Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda
Abdul Aziz, 50300 Kuala Lumpur, Malaysia. 5Toxicology Laboratory, Faculty of
Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz,
50300 Kuala Lumpur, Malaysia.
Received: 13 April 2014 Accepted: 15 July 2014
Published: 9 August 2014
References
1. Tortora GJ, Derrickson B: The Urinary System. In Principle of Anatomy and
Physiology. Volume 712. 11th edition. Edited by Roesh B. United States of
America: John Wiley & Sons Inc; 2006:1023–1024.
2. Chester JD, Hall GD, Forster M, Protheroe AS: Systemic chemotherapy
for patients with bladder cancer- current controversies and future
directions. Cancer Treat Rev 2004, 30:343–358.
3. Chandrasoma P, Clive R: The Ureters, Urinary Bladder & Urethra. In Taylor:
Concise Pathology. 3rd edition. New York: McGraw-Hill Publishing Co;
2001:739–745.
4. de Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, Sternberg
CN: Bladder cancer. Crit Rev Oncol Hematol 2002, 41:89–106.
5. Page BH, Levison VB, Curwen MP: The site of recurrence of non-infiltrating
bladder tumours. Br J Urol 1978, 50:237–242.
6. Melicow MM: Tumors of the bladder: a multifaceted problem. J Urol 1974,
112:467–478.
7. Doherty SC, McKeown JA Lopez SR, Walsh IK, McKelvey-Martin VJ: Gene
expression in normal urothelium depends on location within the bladder:
a possible link to bladder carcinogenesis. J Eur Urol 2006, 50:290–301.
8. Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T: The
human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to
alzheimer’s disease-associated neurodegeneration and oxidative stress.
J Neurosci 2000, 20:7345–7352.
9. Waterham HR, Koster J, Romeijn GJ, Hennekam RCM, Vreken P, Andersson HC,
FitzPatrick DR, Kelley RI, Wanders RJA: Mutations in the 3b-Hydroxysterol
D24-reductase gene cause desmosterolosis, an autosomal recessive
disorder of cholesterol biosynthesis. Am J Hum Genet 2001, 69:685–694.
10. Crameri A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S, Dotti CG,
Nitsch RM, Ledesma MD, Mohajeri MH: The role of seladin-1/DHCR24 in
cholesterol biosynthesis, APP processing and Aβ generation in vivo.
EMBO J 2006, 25:432–443.
11. Sarkar D, Imai T, Kambe F, Shibata A, Ohmori S, Siddiq A, Hayasaka S,
Funahashi H, Seo H, The Human Homolog of Diminuto/Dwarf1 Gene
(hDiminuto): A novel ACTH-responsive gene overexpressed in benign
cortisol-producing adrenocortical adenomas. J Clin Endocrinol Metab 2001,
86:5130–5137.
12. Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, Mantovani
G, Cellai I, Ammannati F, Spada A, Serio M, Peri A: Expression of the
antiapoptotic gene seladin-1 and octreotide-induced apoptosis in
growth hormone- secreting and nonfunctioning pituitary adenomas.
J Clin Endocrinol Metab 2005, 90(11):6156–6161.
13. Bonaccorsi L, Luciani P, Nesi G, Mannucci E, Deledda C, Dichiara F, Paglierani
M, Rosat F, Masieri L, Serni S, Carini M, Proietti-Pannunzi L, Monti S, Forti G,
Danza G, Serio M, Peri A: Androgen receptor regulation of the seladin-1/
DHCR24 gene: altered expression in prostate cancer. Lab Investig 2008,
88:1049–1056.
14. Stasi D, Vallacchi V, Campi V, Ranzani T, Daniotti M: DHCR24 gene
expression is upregulated in melanoma metastases and associated to
resistance to oxidative stress-induced apoptosis. Institute J Cancer 2005,
115:224–230.15. Wu C, Miloslavvskaya I, Demontis S, Maestro R, Galaktionov K: Regulation of
cellular response to oncogenic and oxidative stress by sealdin-1. Nature
2004, 432:640–645.
16. Khuda II-E, Koide N, Noman ASM, Dagvadorj J, Tumurkhuu G, Naiki Y, Ti K, Ti Y,
Ti Y: Seladin-1 is a novel lipopolysaccharide (LPS)-responsive gene and
inhibits the tumour necrosis factor-a production and osteoclast formation
in response to LPS. Immunol J Cells Mol System Technol 2010, 131:59–66.
17. Inayat-Hussain SH, Osman AB, Din LB, Ali AM, Snowden RT, MacFarlane M,
Cain K: Caspases-3 and -7 are activated in goniothalamin-induced
apoptosis in human Jurkat T-cells. FEBS Lett 1999, 456:379–383.
18. Inayat-Hussain SH, Annuar BO, Din LB, Ali AM, Ross D: Loss of
mitochondrial transmembrane potential and caspase-9 activation during
apoptosis induced by the novel styryl-lactone goniothalamin in HL-60
leukemia cells. Toxicol Vitro 2003, 17:433–439.
19. Ali AM, Mackeen HM, Aun QB, Zauyah Y, Azimahtol HL, Kawazu K:
Cytotoxicity and electron microscopy of cell death induced by
goniothalamin. Planta Med 1997, 63:81–83.
20. Pihie AH, Stanslas J, Din LB: Non-steroid receptor-mediated antiprolif-
erative activity of styrylpyrone derivative in human breast cancer cell
lines. Anticancer Res 1998, 18:1739–1743.
21. Rajab NF, Hamid ZA, Hassan H, Ali MA, Din LB, Inayat-Hussain SH: Evaluation
of the cytotoxic and genotoxic effects of goniothalamin in leukemic cell
lines. Environm Mutagen Res 2005, 27:161–164.
22. Chen WY, Wu CC, Lan YH, Chang FR, Teng CM, Wu YC: Goniothalamin
induces cell cycle-specific apoptosis by modulating the redox status in
MDA- MB-231 cells. Eur J Pharmacol 2005, 522:20.
23. de fa Tima A, Kohn LK, Ernesto de Carvalhob J, Pilli RA: Cytotoxic activity of
(S)-goniothalamin and analogues against human cancer cells. Bioorg Med
Chem 2006, 14:622–631.
24. Vendramini-Costa DB, Daltro de Castro IB, Tasca Góis Ruiz AL, Marquissolo C,
Pilli RA, de Carvalho JE: Effect of goniothalamin on the development of
Ehrlich solid tumor in mice. Bioorg Med Chem 2010, 18:6742–6747.
25. Chan KM, Rajab NF, Siegel D, Din LB, Ross D, Inayat-Hussain SH: Goniothalamin
induces coronary artery smooth muscle cells apoptosis: the p53-dependent
caspase-2 activation pathway. Toxicol Sci 2010, 116(2):533–548.
26. Jewers K, Davis JR, Dougan J, Machanda AH, Blunden G, Kyi A, Wetchapinan
S: Goniothalamin and its distribution in four goniothalamus species.
Phytochemistry 1972, 11:2025–2030.
27. Mosmann T: Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Meth 1983,
65:55–63.
28. Chan KM, Rajab NF, Ishak MHA, Ali AM, Yusoff K, Din LB, Inayat-Hussain SH:
Goniothalamin induces apoptosis in vascular smooth muscle cells. Chem
Biol Interact 2006, 159(2):129–140.
29. Chresta CM, Masters JRW, Hickman JA: Hypersensitivity of human
testicular tumors to etoposide-induced apoptosis is associated with
functional p53 and a high Bax: Bcl-2 ratio. Cancer Res 1996, 56:1834–1841.
30. Al-Sukhun S, Hussain M: Current understanding of the biology of
advanced bladder cancer. Cancer 2003, 97(8):2064–2075.
31. Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM: The role of
phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell
Death Differ 1998, 5:551–562.
32. Denecker G, Dooms H, VL G, Vercammen D, Grooten J, Fiers W, Declercq W,
Vandenabeele P: Phosphatidyl serine exposure during apoptosis
precedes release of cytochrome c and decrease in mitochondrial
transmembrane potential. FEBS Lett 2000, 465(1):47–52. 7.
33. Wiart C, Goniothalamus Species: A source of drugs for the treatment of
cancers and bacterial infections? Evidence-Based Compl Alternat Med 2007,
4(3):299–311.
doi:10.1186/1472-6882-14-295
Cite this article as: Yen et al.: Involvement of Seladin-1 in goniothalamin-
induced apoptosis in urinary bladder cancer cells. BMC Complementary and
Alternative Medicine 2014 14:295.
